Drug General Information
Drug ID
D05CEO
Former ID
DNCL003320
Drug Name
Brodalumab
Synonyms
AMG 827
Drug Type
Monoclonal antibody
Indication Severe plaque psoriasis [ICD10:L40] Approved [889446]
Psoriasis [ICD9: 696; ICD10:L40] Phase 3 [524588], [542542]
Asthma [ICD10:J45] Phase 2 [542542], [550248]
Company
Valeant Luxembourg
Target and Pathway
Target(s) Interleukin-17 Target Info Modulator [556264]
KEGG Pathway Cytokine-cytokine receptor interaction
Inflammatory bowel disease (IBD)
Rheumatoid arthritis
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database IL27-mediated signaling events
IL23-mediated signaling events
WikiPathways TCR Signaling Pathway
Allograft Rejection
IL17 signaling pathway
References
Ref 524588ClinicalTrials.gov (NCT02029495) Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis. U.S. National Institutes of Health.
Ref 542542(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7540).
Ref 550248Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
Ref 889446Drugs@FDA (Edaravone)
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.